Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2010-10, Vol.20 (5), p.528-530 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 530 |
|---|---|
| container_issue | 5 |
| container_start_page | 528 |
| container_title | Modern rheumatology |
| container_volume | 20 |
| creator | Onishi, Sachiko Yoshio, Taku Nagashima, Takao Minota, Seiji |
| description | |
| doi_str_mv | 10.3109/s10165-010-0305-7 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_20458607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20458607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2717-85a391039615692b077cc8ccd5642fa806a69e5817e5c106bd8019ce680910ff3</originalsourceid><addsrcrecordid>eNp9kEFu1TAURSNERUthAUyQNxB4_vl2YsEEtbSAKnUCY-t9-0VxldiR7VD97bADNsKacAhFYgAjW_I911enql5weNVwUK8TBy5FDRxqaEDU7aPqjO8bVbcS1OOHu1DitHqa0h1AI1SnnlSnO9iLTkJ7Vn27JBMJEzHnWR6IjfSVxsRCz9BnV5ujGZ1hxuW4jKPzmMmymebsLP1KHII9ruwnnNFT6ZkxO_I5sXuXBxYHWibMwVmGMQ_RZVdehsAipTl4W9py2L7KyxQi82VPSCXUo8kh1j--P6tOehwTPf99nldfrt5_vvhQ39xef7x4d1ObXcvbuhPYKA6NklxItTtA2xrTGWOF3O967ECiVCQ63pIwHOTBdsCVIdlBwfq-Oa_41rsOSJF6PUc3YTxqDnr1rTffuvjWq2_dFublxszLYSL7h3gQXAJvt4DzfYgT3oc4Wp3xOIbYR_TGpbX73_1v_sIHwjEPBiPpu7BEX3z8Z91PGqCmew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>SpringerLink Journals - AutoHoldings</source><creator>Onishi, Sachiko ; Yoshio, Taku ; Nagashima, Takao ; Minota, Seiji</creator><creatorcontrib>Onishi, Sachiko ; Yoshio, Taku ; Nagashima, Takao ; Minota, Seiji</creatorcontrib><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.3109/s10165-010-0305-7</identifier><identifier>PMID: 20458607</identifier><language>eng</language><publisher>United States: Informa Healthcare</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anti-cyclic citrullinated peptide antibody ; Anti-TNF agents ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - physiopathology ; Biomarkers - blood ; Drug Therapy, Combination ; Etanercept ; Health Status ; Humans ; IgG ; IgM rheumatoid factor ; Immunoglobulin G - blood ; Immunoglobulin G - therapeutic use ; Immunoglobulin M - blood ; Methotrexate - therapeutic use ; Middle Aged ; Peptides, Cyclic - immunology ; Receptors, Tumor Necrosis Factor - therapeutic use ; Rituximab ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Young Adult</subject><ispartof>Modern rheumatology, 2010-10, Vol.20 (5), p.528-530</ispartof><rights>2010 Japan College of Rheumatology 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2717-85a391039615692b077cc8ccd5642fa806a69e5817e5c106bd8019ce680910ff3</citedby><cites>FETCH-LOGICAL-c2717-85a391039615692b077cc8ccd5642fa806a69e5817e5c106bd8019ce680910ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20458607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onishi, Sachiko</creatorcontrib><creatorcontrib>Yoshio, Taku</creatorcontrib><creatorcontrib>Nagashima, Takao</creatorcontrib><creatorcontrib>Minota, Seiji</creatorcontrib><title>Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-cyclic citrullinated peptide antibody</subject><subject>Anti-TNF agents</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Biomarkers - blood</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept</subject><subject>Health Status</subject><subject>Humans</subject><subject>IgG</subject><subject>IgM rheumatoid factor</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunoglobulin M - blood</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Peptides, Cyclic - immunology</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Rituximab</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Young Adult</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFu1TAURSNERUthAUyQNxB4_vl2YsEEtbSAKnUCY-t9-0VxldiR7VD97bADNsKacAhFYgAjW_I911enql5weNVwUK8TBy5FDRxqaEDU7aPqjO8bVbcS1OOHu1DitHqa0h1AI1SnnlSnO9iLTkJ7Vn27JBMJEzHnWR6IjfSVxsRCz9BnV5ujGZ1hxuW4jKPzmMmymebsLP1KHII9ruwnnNFT6ZkxO_I5sXuXBxYHWibMwVmGMQ_RZVdehsAipTl4W9py2L7KyxQi82VPSCXUo8kh1j--P6tOehwTPf99nldfrt5_vvhQ39xef7x4d1ObXcvbuhPYKA6NklxItTtA2xrTGWOF3O967ECiVCQ63pIwHOTBdsCVIdlBwfq-Oa_41rsOSJF6PUc3YTxqDnr1rTffuvjWq2_dFublxszLYSL7h3gQXAJvt4DzfYgT3oc4Wp3xOIbYR_TGpbX73_1v_sIHwjEPBiPpu7BEX3z8Z91PGqCmew</recordid><startdate>201010</startdate><enddate>201010</enddate><creator>Onishi, Sachiko</creator><creator>Yoshio, Taku</creator><creator>Nagashima, Takao</creator><creator>Minota, Seiji</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201010</creationdate><title>Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α</title><author>Onishi, Sachiko ; Yoshio, Taku ; Nagashima, Takao ; Minota, Seiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2717-85a391039615692b077cc8ccd5642fa806a69e5817e5c106bd8019ce680910ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-cyclic citrullinated peptide antibody</topic><topic>Anti-TNF agents</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Biomarkers - blood</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept</topic><topic>Health Status</topic><topic>Humans</topic><topic>IgG</topic><topic>IgM rheumatoid factor</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunoglobulin M - blood</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Peptides, Cyclic - immunology</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Rituximab</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onishi, Sachiko</creatorcontrib><creatorcontrib>Yoshio, Taku</creatorcontrib><creatorcontrib>Nagashima, Takao</creatorcontrib><creatorcontrib>Minota, Seiji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onishi, Sachiko</au><au>Yoshio, Taku</au><au>Nagashima, Takao</au><au>Minota, Seiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2010-10</date><risdate>2010</risdate><volume>20</volume><issue>5</issue><spage>528</spage><epage>530</epage><pages>528-530</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><cop>United States</cop><pub>Informa Healthcare</pub><pmid>20458607</pmid><doi>10.3109/s10165-010-0305-7</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2010-10, Vol.20 (5), p.528-530 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_pubmed_primary_20458607 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Anti-cyclic citrullinated peptide antibody Anti-TNF agents Antibodies, Monoclonal, Murine-Derived - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - physiopathology Biomarkers - blood Drug Therapy, Combination Etanercept Health Status Humans IgG IgM rheumatoid factor Immunoglobulin G - blood Immunoglobulin G - therapeutic use Immunoglobulin M - blood Methotrexate - therapeutic use Middle Aged Peptides, Cyclic - immunology Receptors, Tumor Necrosis Factor - therapeutic use Rituximab Severity of Illness Index Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult |
| title | Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T14%3A40%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decrease%20in%20the%20levels%20of%20anti-cyclic%20citrullinated%20peptide%20antibody%20in%20Japanese%20patients%20with%20rheumatoid%20arthritis%20who%20responded%20to%20anti-tumor%20necrosis%20factor-%CE%B1&rft.jtitle=Modern%20rheumatology&rft.au=Onishi,%20Sachiko&rft.date=2010-10&rft.volume=20&rft.issue=5&rft.spage=528&rft.epage=530&rft.pages=528-530&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.3109/s10165-010-0305-7&rft_dat=%3Cpubmed_cross%3E20458607%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20458607&rfr_iscdi=true |